Roberto Solari

NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018.

AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008.

Pathios Therapeutics Ltd. engages in discovering and developing novel small molecule drugs. The company was founded by Thomas David McCarthy, Alan Naylor, Kirsty McCarthy, Peter Joyce and Someit Sidhu in 2017 and is headquartered in Oxford, the United Kingdom.

Global Kinetics Pty Ltd. provides point of care measurement and reporting of Parkinson's disease motor symptoms. Its product includes Personal KinetiGraph (PKG), a wrist worn medical device which reminds the patient when they have taken Levodopa medication as prescribed by doctor. The company was founded by Robert Griffiths and Malcolm Horne in 2007 and is headquartered in Melbourne, Australia.

Denteric Pty Ltd. is a biotechnology company focused on oral health. It provides developing vaccines for treating and preventing severe periodontal disease. The company was founded by Eric C. Reynolds and is headquartered in Melbourne, Australia.

Q-Sera Pty Ltd. develops, manufactures and markets blood serum collection tubes. The company was founded in 2012 and is headquartered in Melbourne, Australia.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Artios Pharma Ltd. manufactures pharmaceutical products. The firm develops a DNA Damage Response (DDR) is a cancer therapy. The company was founded by Niall Martin in May 2016 and is headquartered in London, the United Kingdom.

Cardiora Pty Ltd. functions as a clinical stage pharmaceutical company. It develops CRD-102, an oral medicine for heart failure. The company was founded by David Kaye in 2015 and is headquartered in Melbourne, Australia.

The University of Melbourne, founded in 1853, is a world-renowned institution located in Parkville, Australia. The university is a leader in education, teaching, and research, offering a wide range of coursework and research programs.

Respirion Pharmaceuticals Pty Ltd. operates as a biotechnology firm. It focuses on development new treatments for respiratory diseases. The company was founded by Barry Clements in 2018 and is headquartered in Iluka, Australia.

QUE Oncology, Inc. engages in preventing and treating life-threatening cancers such as prostate cancer, breast cancer, melanoma, and cancer pain; and related conditions. The company is headquartered in Atlanta, GA.

OncoRes Medical Pty Ltd. develops an imaging medical device which provides micro-scale images of tissue stiffness and elasticity information to surgeons. The company is headquartered in Nedlands, Australia.

Longas Technologies Pty Ltd. is engaged in developing next generation sequencing (NGS) technologies. The company was founded by Ian Charles, Aaron Darling, and Catherine Burke in 2015 and is headquartered in Sydney, Australia.

LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark.

Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.

Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom.

Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London.

Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Contera Pharma ApS is a holding company that identifies and develops treatments for patients suffering from movement disorders. It develops drug candidates based on a combination of repositioning, combinations, and reformulations. The firm's lead project JM-010 is for treatment of dyskinesia associated with Parkinson's disease. It develops an approach of using a combination therapy to tackle clinically relevant synergistic pathways to obtain therapeutic effects which will generate efficacious therapeutic entities based on robust pre-clinical and clinical evidence. The company was founded by Mikael Søndergaard Thomsen and John Bondo Hansen in 2010 and is headquartered in Copenhagen, Denmark.

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

Medical Research Commercialisation Fund Trust invests in life science companies located in Australia. The fund focuses on companies operating in the fields of medical research institutes and allied research hospitals. It provides seed and early stage financing in project investment of up to $0.02 million, at the stage of company formation invests up to $4 million and also makes follow-on investments of up to $2 million. It seeks co-investment with other investors for technologies with larger capital requirements.

Australian Investment Council is an Australian private company located in Sydney. The firm operates as an association. Navleen Prasad has been the CEO since 2022.

Certa Therapeutics Pty Ltd. operates as biotechnology company. The firm develops drugs for treatment for kidney disease. The company was founded by Darren James Kelly and is headquartered in Melbourne, Australia.

Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom.

MetabloQ Pty Ltd. develops drugs for cancer treatment. It treats triple-negative breast cancer, prostate cancer and melanoma cancer diseases. The company was founded in 2016 and is headquartered in Melbourne, Australia.

Ankere Therapeutics develops therapeutics for inflammatory diseases. The Australian company was founded by Stuart Pitson, Bernard Flynn. Bernard Flynn has been the CEO since incorporation.